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Abstract
Men living in Fiji and drinking kava have low incidence of prostate cancer (PCa). However, the PCa incidence among Fijian
men who had migrated to Australia, increased by 5.1-fold. We therefore examined the potential effects of kava root extracts
and its active components (kavalactones and flavokawains) on PCa growth and androgen receptor (AR) expression. PCa cell
lines (LNCaP, LAPC-4, 22Rv1, C4-2B, DU145 and PC-3) with different AR expression, and a transformed prostate
myofibroblast cell line (WPMY-1), were treated with a commercial kava extract, kavalactones (kawain, 5969-dehydrokawain,
yangonin, methysticin) and flavokawain B. Expression of AR and its target genes (PSA and TMPRSS2) was examined. Two
novel patient-derived PCa xenograft models from high grade PCa specimens were established by implanting the specimens
into nude mice and passing tumor pieces through subcutaneous injection in nude mice, and then treated with kava extract
and flavokawain B to examine their effects on tumor growth, AR expression and serum PSA levels. The kava extract and
flavokawain B effectively down-regulated the expression of both the full-length AR and AR splice variants. The kava extract
and kavalactones accelerated AR protein degradation, while flavokawain B inhibited AR mRNA transcription via decreasing
Sp1 expression and the binding of Sp1 to the AR promoter. The kava root extract and flavokawain B reduce tumor growth,
AR expression in tumor tissues and levels of serum PSA in the patient-derived PCa xenograft models. These results suggest a
potential usefulness of a safe kava product or its active components for prevention and treatment of advanced PCa by
targeting AR.
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Introduction
Asian/Pacific men who consume a low fat and plant-based diet
have the lowest rates of clinical PCa in the world [1,2]. However,
when Asian men migrate to the US, rates of clinical PCa increase
[3]. These observations implicate both environmental factors and
dietary habits (such as consumption of low-fat and plant-based
diet) in PCa development. Therefore, one of strategies for
prevention and treatment of PCa has focused on the use of
natural and synthetic bioactive food components.
Kava (Piper methysticum Forst) is a perennial plant indigenous to
the Pacific Islands. Kava root and rhizome are used to prepare a
non-fermented and ceremonial beverage with relaxant effects in
the Pacific Islands for thousands of years [4]. Unusually low
incidences of several cancers, including lung and prostate cancer,
are reported in the Pacific Island nations despite a high portion of
smokers in these populations [2,5]. In addition, Steiner [6]
reported that the age-standardized cancer incidence for the three
highest kava-drinking countries (Vanuatu, Fiji, and Western
Samoa) was one fourth or one third that of non-kava-drinking
countries, such as New Zealand and United States (Hawaii and
Los Angeles), and non-kava-drinking Polynesians (Maoris).
Uniquely, in these three kava-drinking countries more men drink
kava and smoke than do women, yet there is a lower incidence of
cancer for men than for women [6]. Moreover, the Cancer
Council’s Cancer in New South Wales (NSW) Migrants 1991–
2001 report found [7] that the PCa incidence in Fijian men who
migrated to and were resident in NSW, Australia, increased by 5.1
times compared to those living in Fiji. This report has prompted us
to investigate the potential benefits of kava extracts and its active
components for PCa prevention.
We report for the first time that a commercial kava extract and
its active components (kavalactones and flavokawain B) down-
regulate AR expression. Depletion of AR protein occurred
through two different mechanisms: 1) enhanced AR protein
degradation, and 2) reduced Specificity protein 1 (Sp1)-mediated
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31213AR transcription. Kava extract and flavokawain B treatment of
mice with patient-derived xenografts reduced tumor growth and
expression of AR and its target genes in tumor tissues, and lowered
serum PSA levels.
Methods
Ethics statement
Use of mice and their care for this study was specifically
approved by the University of California, Irvine Institutional
Animal Care and Use Committee (IACUC; protocol number
2007–2741).
Cell lines, compounds and reagents
The LNCaP, LAPC4, 22Rv1, PC3, DU145, and WPMY-1 cell
lines were obtained from American Type Culture Collection
(ATCC) (Manassas, VA), and C4-2B cell line was from Urocor
Inc. (Oklahoma City, OK). These cells were cultured in RPMI
1640 medium with 10% fetal bovine serum (FBS). All cell lines
used in this study were within 20 passages after receipt. The cell
lines were tested and authenticated by ATCC or Urocor Inc. All
cells lines were also tested for known species of mycoplasma
contamination using a kit from LONZA Inc. (Walkersville, MD).
Pure kawain, 59,6 9-dehydrokawain, yangonin, methysticin, and
flavokawain B (99%) were isolated from kava extracts by LKT
Laboratories, Inc. (St. Paul, MN). Kava root extract at a
concentration of 150 mg/ml kavalactones in 50% ethanol was
obtained from Gaia Herbs (Brevard, NC). Antibodies against AR
and tubulin were from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA). PSA and Sp1 antibodies were purchased from Thermo
Scientific (Fremont, CA). 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphe-
nyltetrazolium bromide (MTT) was from Sigma. RNAzol B was
purchased from Tel-Test (Friendswood, TX.). The Reverse
Transcription System kit and was from Promega (Mandison,
WI). A quantitative RT-PCR kit was from Bio-Rad (Hercules,
CA).
Measurement of kavalactones and flavokawains in the
kava root extract
The kava extract was diluted 400 times by acetronitrile, and
then filtered with 0.45 mm solvent resistant filters and stored at
280uC until further analysis. Chromatography was performed on
an Acquity Ultra Performance Liquid Chromatography (UPLC)
system (Waters Corp., Milford, MA, USA) with an auto-sampler at
8uC. Separation of compounds was carried out at 50uC using a
Waters Acquity UPLC HBEH C18 1.7 mm (2.1650 mm) column
with a gradient elution: (A) Water: Acetonitrile: acetic acid
(97.8:2:0.2 v/v/v), and (B) Acetonitrile: acetic acid 99.8:0.2 (v/v)
as the mobile phase.
The elution program was as follows: 10% B (initial), 90% B
(1.0 min), 90% B (2.0 min), 10%B (2.05 min), and 10% (3 min).
The flow rate was 0.3 mL/min and the injection volume was
10 mL. The UPLC was coupled to Micromass Quattro Micro
Liquid chromatography–mass spectrometry (LC/MS/MS) triple
quadrupole mass spectrometer (Mass Range: 2,2000 m/z) with
electrospray ionization (ESI) interface in positive mode. The
instrument was operated in a positive ion mode with an ESI
voltage of 3.8 kV, and a desolvation gas flow of 700 L/h. Argon
was used as the collision induced dissociation gas at a pressure of
7.1
e23 mbar with a selected reaction monitoring transition for
flavokawain A of m/z 315.m/z 181, flavokawain B of 284.181,
kawain of 231.115, 59,6 9-dehydrokawain of 229.131, mythys-
ticin of 275.159, Yangonin of 259.161.
MTT assay
Cells were plated at a density of 2610
4 per well in 24-well
culture plates for 24 hours, and then treated as indicated in the
figures. After treatment for 72 hours, 1 mg/mL MTT was added
to each well for 2 hours, and the absorbance was determined at
570 nm. Dose–response curves for growth inhibition were
generated as a percentage of vehicle-treated controls.
Western blot analysis
Clarified protein lysates (20–100 mg) were denatured and
resolved by 8–16% SDS-PAGE. Proteins were transferred to
nitrocellulose membranes, and probed with indicated antibodies
and visualized by an enhanced chemiluminescence detection
system.
Quantitative RT-PCR
Real-time quantitative PCR amplification reactions for AR,
prostate specific antigen (PSA) and Transmembrane protease,
serine 2 (TMPRSS2) mRNA levels were carried out using MyiQ
system (Bio-Rad) as described previously [8,9]. The sequences of
primers for AR, PSA and TMPRSS2 are available upon request.
Data were analyzed by using the comparative Ct method, where
Ct is the cycle number at which fluorescence first exceeds the
threshold. The Ct values from each sample were obtained by
subtracting the values for beta-actin Ct from the target gene Ct
value. The variation of beta actin Ct values is ,0.5 among different
samples. A one cycle difference of Ct value represents a 2-fold
difference in the level of mRNA. Specificity of resulting PCR
products was confirmed by melting curves and agarose gel.
Transfection, promoter activity and luciferase Assay
The PSA-Luc and plARS-Luc plasmids are a kindly gift from
Dr. Wang Longgui (New York University Cancer Institute).
Human Sp1-HA tagged plasmid was kindly provided by Macus
Tien Kuo (The University of Texas M. D. Anderson Cancer
Center). C4-2B and LNCaP cells were co-transfected with PSA-
Luc or plARS-Luc and Renilla luciferase plasmid pGL 4.71
(Promega) or with Sp1-HA plasmid by Lipofectamine 2000
(Invitrogen). After 48 hours, flavokawain B was added as
indicated with triple replications. Then cells were harvested and
luciferase activity was measured with the Dual-Glo Luiferase
assay system (Promega). Renilla luminescence was used as an
inner control for cell numbers and transfection efficiency. The
relative ratio of luminescence from interested gene promoter to
Renilla luminescence was shown in the figures as promoter
activity. For Sp1 transfection, cells were harvest for an
immunoblotting assay.
Chromatin Immunoprecipitation (ChIP) [10]
LNCaP and C4-2B cells were cross-linked by formaldehyde.
The protein/DNA complex was sheared to 500–1500 bp
fragments by sonication. Equal amounts of protein (4 mg) were
incubated with Sp1 antibody, or with a mouse anti-GFP antibody.
Protein G sepharose beads (Sigma) was employed to pull down the
complex, followed by washing with High Salt Wash Buffer, LiCl,
and TE buffers). The DNA-protein immunoprecipitates were
eluted from the beads and the DNA was extracted and purified.
Expand High-Fidelity PCR System (Roche) was used to amplify
the sequence from +248 to +487 nucleotides of the AR 59-UTR
region, containing two Sp1 binding sites. Primer sequences are
available upon request.
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models
Prostatectomy tissues were obtained through an IRB-approved
protocol at UCI Medical Center. Small fragments of histologically-
proven tumor were implanted into 8-week-old male Severe
combined immunodeficiency (SCID) mice using a subrenal
xeongraft technique [11]. Tumors designated as GM0308 and
RC0309 at 3 and 13 murine passages respectively, were re-
implanted into subcutaneous pockets of SCID mice. One week
later, when the tumors grew to about 100 mm
3, mice were
randomized into treatment groups. For the kava extract treatment,
mice were fed a standard diet supplemented with either vehicle
control or 6 g/kg kava extract in the diet. For the flavokawain B
treatment, mice were injected intraperitoneally each day with
vehicle control (10% DMSO, 20% ethanol and 70% Cremophor)
or 200 mg flavokawain B/kilogram mouse body weight. Treat-
ment was continued from day 0 to day 17 for the kava extract and
to day 27 for flavokawain B. Tumor growth was monitored by
both serum PSA and caliper measurement of tumor size weekly.
Body weight and food intakes were recorded during the
experiments. At the end of the experiments, tumor tissues were
weighed and cut in half for mRNA isolation and immunohisto-
chemistry staining, respectively. The tumor volume was calculated
by the formula: 0.52366L16(L2)
2, where L1 is the long axis and L2
is the short axis of the tumor. Serum PSA concentration was
determined by PSA Enzyme-linked immunosorbent assay kit (Bio-
Quant, San Diego, CA) following the kit’s instruction.
Immunohistochemistry
Antigen was retrieved using 0.05 M Glycine-HCL buffer,
pH 3.5, containing 0.01% (w/v) EDTA, at 95uC for 20 min and
stained with anti-human AR (1:100). Staining was visualized with
diaminobenzadine using the Cell and Tissue Staining kit (R&D
Systems).
Statistical analysis
Comparisons of quantitative RT-PCR and promoter assays
between treatment and control experiments were conducted using
Student’s t test. For tumor growth experiments, repeated-measures
ANOVA was used to examine the differences in tumor sizes
among treatments, time points, and treatment-time interactions.
Additional post-tests were done to examine the differences in
tumor sizes between control, the kava extract, and flavokawain B
treatment at each time point by using the conservative Bonferroni
method. All statistical tests were two sided.
Results
The kava extract and its active components (kavalactones
and flavokawain B) differentially inhibit the growth of AR
expressing cells
Kavalactones and chalcones (i.e. flavokawains) are two
important classes of bioactive compounds identified from kava
extracts. Using UPLC, we measured the contents of kavalactones
and flavokawains. The commercial kava extract dissolved in
ethanol and used here contained 2.7% kawain, 1.75% 5, 6-
dehydrokawain, 3.08% Yangonin, 1.4% methysticin, 0.33%
flavokawain B, and 0.21% flavokawain A (Figure 1). To examine
the potential of the kava extract components to inhibit PCa
growth, PCa cell lines and a transformed prostate myofibroblast
line were treated with the kava extract, kavalactones and
flavokawain B. The cell lines vary in their expression of AR
proteins, as well as their androgen dependence. Figure 2 and
Table 1 show that the kava root extract similarly inhibited
androgen sensitive and insensitive PCa cell lines. The kava root
extract was more potent than kavalactones but less potent than
flavokawain B in inhibiting the growth. Among the kavalactones,
5, 6-dehydrokawain is the most potent agent in inhibiting the
growth of PCa cell lines (Figure 2 and Table 1). Both the kava root
extract and 5, 6-dehydrokawain equally in inhibiting the growth of
LNCaP and its derivative C4-2B, while flavokawain B was about
Figure 1. UPLC analysis of kavalactones and flavokawain B in
the kava root extract.
doi:10.1371/journal.pone.0031213.g001
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than the growth of LNCaP cells. Given that the kava extract has
much less flavokawain B and more 5, 6-dehydrokawain, this result
suggest that 5, 6-dehydrokawain or its combination with other
active components may play a dominant role for the inhibitory
effect of the kava extract on the growth of PCa cell lines.
Kava root extract and kavalactones decrease the
expression of PSA and TMPRSS2 through acceleration of
AR protein degradation
Figure 3A shows that the kava extract and kavalactones (i.e.
kawain, 5969-dehydrokawain, yangonin, and methysticin) mark-
edly down-regulate the mRNA expression of AR target genes (PSA
and TMRSS2) but not mRNA expression of AR in C4-2B cells.
Figure 3B and C shows that both the kava extract and individual
kavalactones decrease AR and PSA protein expression as well.
The growth inhibitory effect of the kavalactones correlated poorly
with their effects on AR protein down-regulation. C4-2B cells, an
androgen-independent LNCaP derivative, were more sensitive to
the AR down-regulating effect of the kavalactones and the kava
extract than were LNCaP cells.
We next examined the stability of AR protein by treating the
cells with cycloheximide to inhibit new protein synthesis. Figure 3D
demonstrates that AR protein exhibits an accelerated degradation
in C4-2B cells treated with either the kava extract or 5969-
dehydrokawain, when compared with its stability in vehicle-
treated cells. At 16 and 24 hours of treatments, the kava extract
and 5969-dehydrokawain treatments decrease AR protein levels by
Figure 2. The effect of the kava root extract and its active components on the growth of PCa cell lines (C4-2B, LNCaP, 22Rv1, LAPC-
4, DU145 and PC3) and a prostate myofibroblast WPMY-1. Cells in 24-well culture plates were treated with 0.1% DMSO, the kava root extract,
kawain, 59,6 9-dehydrokawain, yangonin, methysticin, or flavokawain B (FKB) at the indicated doses. After 72 hours of treatment, cell densities were
measured by MTT assay. Each point is the mean of values from four independent plates; bars, SD. Each sample was counted in duplicate. IC50 s were
estimated by dose-response curves.
doi:10.1371/journal.pone.0031213.g002
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vehicle control only decrease by about 20% and 37%, respectively
(Figure 3D).
Flavokawain B down-regulates the expression of AR and
its target genes (PSA and TMPRSS2)
Flavokawain B is the most potent agent for inhibiting cell
growth among the examined bioactive components of the kava
extract. We therefore investigated the effect of flavokawain B on
AR expression. Figure 4A shows that flavokawain B significantly
decrease AR protein expression in all AR expressing cell lines
(LAPC4, C4-2B, WPMY-1, LNCaP and 22Rv1). Interestingly, the
AR protein level in WPMY-1 cells is the most sensitive to
flavokawain B treatment. Since WPMY-1 represents a trans-
formed prostate myofibroblast line [12], this result suggests that
flavokawain B may be a novel agent for targeting PCa stromal AR.
Flavokawain B also decreased the protein levels of PSA (Figure 4A).
Figure 4B shows that flavokawain B inhibits the expression of AR
and PSA proteins induced by a synthetic androgen analog, R1881.
Pre-treatment with a proteasome inhibitor, MG132, did not
recover the flavokawain B down-regulated-AR protein level
(Figure 4C). In contrast to the kava extract and kavalactones
treatments, treatment of LNCaP and C4-2B cells with 5 mg/ml
flavokawain B for 4 and 8 hours resulted in a marked decrease in
the mRNA levels of AR and its target genes (PSA and TMPRSS2)
(Figure 4D). These results suggest that flavokawain B-mediated
AR down-regulation is through its transcriptional regulation.
The transcriptional suppression of AR by flavokawain B
requires the expression of transcriptional factor Sp1
We next investigated potential mechanism of flavokawain B
mediated AR transcription. Sp1 is a putative transcriptional factor
for AR regulation. Sp1 directly binds to the GC-box in the AR
promoter through a zinc-finger protein motif [13,14]. Therefore,
an AR promoter luciferase reporter that contains four Sp1 binding
sites was used to assay AR promoter activity in PCa cell lines.
Figure 5A shows that flavokawain B treatments markedly decrease
AR promoter activity in a dose-dependent fashion. The decrease
in AR promoter activity by flavokawain B was associated with a
reduction of Sp1 protein levels (Figure 5B). Consequently, ChIP
analysis revealed that flavokawain B treatment of C4-2B and
LNCaP cells markedly inhibited the binding of Sp1 to the AR
promoter sequences (Figure 5C). To examine whether Sp1 is
required for flavokawain B-mediated AR down-regulation, C4-2B
cells were transiently transfected with Sp1 and then treated with
flavokawain B. Figure 5D shows that overexpression of Sp1
increased AR protein levels and attenuated the flavokawain B-
induced AR down-regulation. Taken together, our results clearly
demonstrate that flavokawain B decreases Sp1 protein expression,
leading to AR transcriptional down-regulation.
Kavalactones and flavokawain B combination results in
an enhanced inhibitory effect on growth of C4-2B cells
and on expression of AR protein
Figure 6A and B shows that 7.5 mg/ml yangonin and 1 mg/ml
flavokawain B alone inhibited the growth of C4-2B cells by 15%
and 20%, respectively, while their combination reduced the
growth by more than 70%. Similarly, 5969-dehydrokawain at a
dose of 7.5 mg/ml decreased the growth of C4-2B cells by less than
5%, while its combination with 1 mg/ml flavokwain B inhibited
the growth by about 60%. Consistent with this result, flavokawain
B in combination with other kavalactones (i.e. kawain and
methysticin) also resulted in a synergistic inhibitory effect on the
growth of C4-2B cells (Figure 6C and D). Furthermore,
combination of 5969-dehydrokawain or yagonin with flavokawain
B treatments resulted in an enhanced down-regulation of AR
protein expression in both C4-2B and 22Rv1 cells (Figure 6 E and
F). Notably, 22Rv1 harbors an AR splicing variant with a
molecular weight of about 80 KD [15]. Flavokawain B and 5969-
dehydrokawain are more effective in decreasing the expression of
the AR splicing variant than that of the AR full length (Figure 6F).
These results indicate that kavalactones and flavokawain B act
synergistically or additively to inhibit growth of PCa cells and to
down-regulate protein expression of AR and the AR splice variant.
Kava extract and flavokawain B decrease the growth of
patient-derived PCa xenografts in SCID mice, AR
expression in tumor tissues and serum PSA levels
To determine the in vivo anti-PCa effect of the kava extract and
flavokawain B, we developed two more clinically relevant, patient-
derived PCa xenograft models, GM0308 and RC0309. The
GM0308 patient-derived PCa xengrafts line was derived from a
high-grade (gleason score sum=5+5) PCa prostatectomy specimen
obtained from a patient who was previously treated with androgen
deprivation therapy (ADT), docetaxel plus carboplatin, and
Table 1. The IC50 s of the kava root extract and its active components and AR status in prostate cell lines.
Cell lines LNCaP LAPC4 22Rv1 C4-2B WPMY-1 DU145 PC3
Estimated IC50 (mg/mL)
Kava root extract 6.5 35.7 46 7 15 5.4 5.3
Kawain &25 &25 &25 &25 5.21 25 &25
Yangonin &25 &25 .25 7.8 &25 &25 &25
5969Dehydrokawain 15.2 &25 18.75 15.3 25 20.6 22.9
Methysticin &25 &25 &25 23 &25 &25 &25
Flavokawain B 10 5.6 16.6 2.2 2.25 1.5 2.1
AR status* MT WT SP MT WT ND ND
Androgen dependency# AS AD/AS AS/AI AI AS AI AI
*AR status: MT: mutant; SP: splicing variant; WT: wild-type; ND: not detectable.
#Androgen dependency: AD: androgen is required for growth; AS: cells may respond to androgen, but do not require it for growth; AI: cells do not respond to
androgen.
doi:10.1371/journal.pone.0031213.t001
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accelerating the degradation of AR protein. (A). C4-2B cells were treated with 0.1%DMSO, kava root extract, dehydrokawain, kawain, yangonin
and methysticin for 8 hours. mRNA levels of AR and AR target genes (PSA and TMPRSS2) were determined by real-time RT-PCR. Bars are means 6 SD
of three independent quantitative measures. Kava root extract and kavalactones significantly decrease mRNA expression of AR target genes (Student
t test, P,0.01) but not that of AR (P.0.05). (B) and (C). The protein expression of AR and PSA in LNCaP and C4-2B cells after indicated treatments at a
concentration of their IC50 s for 16 hours was analyzed by Western blot. a-Tubulin was detected as a loading control. A representative blot was shown
from three independent experiments. Y=yangonin; M=methysticin; D=596;-dehydrokawain; K=kawain, KRE=kava root extract. (D). C4-2B cells
were pretreated with 10 mg/ml cycloheximide for 2 hours and then supplemented with kava root extract or 596;-dehydrokawain at a concentration of
their IC50 s for different periods of time. After treatments, AR protein levels were analyzed by Western blotting and semi-quantified by densitometry
measurement. A representative blot was shown from three independent experiments.
doi:10.1371/journal.pone.0031213.g003
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established by using a subrenal xenograft technique, and then
passed through subcutaneous injection of tumor pieces. The
RC0309 line was derived from a high-grade (gleason score
sum=5+4) PCa prostatectomy specimen obtained from a patient
who had no previous treatment. These human cancer xenografts
faithfully preserve the histopathological characteristics of the
original clinical sample. Both lines secrete PSA into the host
mouse serum (Figure 6A). The GM0308 line expresses a truncated
AR around 80 KDa, without missense mutations in exons 3, 4, or
5 (data not shown). In contrast, RC0309 holds the full length AR
(data not shown).
Mice bearing GM0308 tumors at passage 3 were treated with
vehicle control or 200 mg/kg flavokawain B daily by IP injection
Figure 4. Flavokawain B (FKB) down-regulates mRNA and protein expression of AR and AR target genes. (A).The protein expression of
AR and PSA after indicated treatments for 16 hours or 5 mg/ml FKB for indicated period of times was analyzed by Western blot. a-Tubulin was
detected as a loading control. A representative blot was shown from three independent experiments. (B).Western blotting analysis shows that FKB
decreases both constitutive and a synthetic androgen, R1881, stimulated AR and PSA expression in LNCaP cell. LNCaP cells were cultured in charcoal
stripped FBS medium. FKB and R1881 at indicated concentrations treated cells for 16 hours. a -Tubulin was detected as a loading control. A
representative blot was shown from three independent experiments. (C). Proteasome inhibitor, MG132, does not affect FKB mediated down-
regulation of AR protein expression. LNCaP cells were treated with MG132 for 2 hours and then added FKB for additional 16 hours. a-Tubulin was
detected as a loading control. A representative blot was shown from three independent experiments. (D). LNCaP and C4-2B cells were treated with
5 mg/ml FKB for 4 and 8 hours. Real-time RT-PCR was performed to analyze mRNA expression of AR and AR target genes (PSA and TMPRSS2). Bars are
mean 6 SD of three independent experiments. FKB significantly decreases mRNA expression of AR target genes (Student t test, P,0.01).
doi:10.1371/journal.pone.0031213.g004
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growth and serum PSA rise during the entire study in vehicle
control group. The flavokawain B treatment, however, resulted in
a decreased rate of tumor growth compared with control group
throughout the study (Figure 7A). The wet tumor weights or serum
PSA in control and flavokawain B–treated group recorded at the
end of the treatment are 0.4360.27 g and 0.09760.048 g, or
66.6612.8 ng/mL and 18.464.8 ng/ml, respectively (mean 6
SD; n=13 for control and n=6 for FKB treatment groups;
P,0.001, Student’s t test). Flavokawain B treatment attenuated
tumor growth by 77.3% and decreased the serum PSA levels by
68% at the end of the treatment.
Mice bearing RC0309 tumors at passage 13 were fed with food
supplemented with vehicle control or 6 g/kg the kava extract for
18 days. Similarly, the kava root extract supplementation resulted
in a significant decrease in the growth rate of tumors compared to
vehicle control (Figure 7B, ANOVA, P,0.01). The wet tumor
weights were 1.8360.79 g in the control group and 0.7360.34 g
in the kava root extract group (Figure 7B; n=5, mean 6 SD;
P,0.05, Student’s t test). The kava extract attenuated tumor
growth by approximately 60.1% and decreased the serum PSA
levels by 42% at the end of the treatment.
Immunohistochemical analysis shows that tumor sections from
the kava extract or flavokawain B treated PCa xenografts
Figure 5. FKB mediated-AR transcriptional repression requires the expression of Sp1. (A).C4-2B cells were co-transfected with PSA-Luc or
plARS-Luc, along with a Renilla luciferase plasmid pGL 4.71 and Luciferase activities were measured. FKB significantly decreases promoter activities of
AR and PSA genes (Student t test, P,0.01). Bars are mean 6 SD of three independent experiments. (B).Western blotting analysis of Sp1 protein
expression. A representative blot was shown from three independent experiments. a -Tubulin was detected as a loading control. (C). ChIP analysis of
the binding of Sp1 to the AR promoter sequence reveals that 16 hours FKB treatment results in a significant decrease in the binding of Sp1 to the AR
promoter sequence that contain two Sp1 binding sites. Mouse IgG was used as a blank control. (D). Overexpression of Sp1 in C4-2B cells attenuates
FKB induced AR protein down-regulation. After 48 hours of Sp1-HA plasmid transfection, C4-2B cells were treated with FKB for 16 hours. Sp1 and AR
protein levels were examined. A representative blot was shown from three independent experiments. a -Tubulin was detected as a loading control.
doi:10.1371/journal.pone.0031213.g005
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positive AR staining cells compared to those of vehicle control
treatments (Figure 7C). Consistently with in vitro results (Figure 4C),
flavokawain B reduced the mRNA expression of AR and its target
genes (PSA and TMPRSS2) by about 84%, 86% and 87%,
respectively, compared to vehicle control treatments (Figure 7D).
The body weight gain and diet and water consumption of the
flavokawain B–treated mice were similar to the control group of
mice (Figure 8, right panels, Student t test, Ps.0.05). In addition,
the mice did not show any gross abnormalities on necropsy.
However, dietary feeding of the commercial kava extract resulted
in a decrease in food up-take, wet spleen and kidney weight, and
body weight, as well as an increase in wet liver weight (Figure 8,
left panels; Student t test, Ps,0.05). These results suggest that
unidentified components of the kava extract, but not flavokawain
B, may be toxic to immunodeficient mice.
Discussion
Androgens and the AR play an essential role in both early and
late PCa. Current approaches targeting androgens/AR in PCa
include treatment with gonadotropin receptor agonists and
antagonists [16], inhibition of 5a-reductase [17,18], inhibition of
the steroidogenic enzyme CYP17A1 [19], blockade of AR ligand
binding (e.g. MDV3100) [20–22] and the AR N-terminal domain
binding (e.g. EPI-001) [23]. Although most of these approaches
have demonstrated their effectiveness in prevention and/or
treatment of PCa and Castration-resistant prostate cancer (CRPC)
in clinics, there are several situations that lead to resistance to the
treatments and worsening disease. First, PCa grows in a complex
and heterogeneous environment, which include different types of
cells (e.g. androgen-dependent and independent PCa cells and
stromal cells). Targeting only androgen-dependent PCa cells
would allow over-population of other types of cells that are not
responsive to the androgen/AR targeting approaches described
above. Second, ADT and the inhibitor of CYP17A1 have been
demonstrated to cause AR overexpression and generation of AR
splice variants that lack the ligand binding C-terminal domain
[19,24]. These treatments would confer ligand-independent AR
transactivation. Suppression of AR expression therefore would
become the straight-forward but efficient strategy for PCa therapy.
Figure 6. FKB and yangonin or 596;-dehydrokawain act synergistically to reduce the growth of C4-2B cells and down-regulate the
expression of the full-length AR and an AR splice variant. The growth inhibitory of FKB and yagonin (A), or 596;-dehydrokawain (B), or kawain
(C), or methysticin (D) alone and in combination on C4-2B cells. Each point is the mean of four independent experiments; bars, SD. Each sample was
counted in duplicate. IC50 s were estimated by dose-response curves, IC50 s of the combinations are significantly lower than those of the treatments alone
(Studentttest,P,0.01).(E)and(F)Westernblottinganalysisofexpressionofthefull-lengthAR(110 KDa),theARsplicevariant(83 KDa)andPSAinC4-2B
and 22Rv1 cells, respectively. A representative blot was shown from three independent experiments. a -Tubulin was detected as a loading control.
doi:10.1371/journal.pone.0031213.g006
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important role in PCa [25]. Targeting stromal AR would have
potentials for PCa prevention and treatment. Therefore, agents
that can potently inhibit the growth of both androgen-dependent
and -independent PCa cells and suppress the expression of AR
splice variants and stromal AR are highly desirable, novel and of
clinical translational values.
We demonstrate that kava extract, kavalactones and flavoka-
wain B can down-regulate the expression of both the full-length
AR and AR splice variants with more potency to expression of an
AR splice variant. In addition, flavokawain B decreases AR
expression in a transformed prostate stromal cell line WPMY-1.
The growth inhibitory effect of the kava extract, kavalactones and
flavokawain B appears not to correlate to AR expression in PCa
cell lines. It is possible that the kava extract, kavalactones and
flavokawain B also have other targets for their growth inhibitory
effect. Taken together, these results suggest that the kava extract
and its active components, specifically flavokawain B, deserve
further investigation of their usefulness in treatment of PCa and
CRPC in particular.
The patient-derived PCa xenografts are thought to more
accurately preserve the histopathological and genotypical charac-
teristics of the original clinical samples [11,26] than do cell line-
derived xenografts. Therefore, the use of this model system in our
study would be more clinically relevant than the current use of cell
lines and transgenic mouse model of PCa. We demonstrate here
that both the kava extract and flavokawain B markedly reduce
tumor weight by about 60 and 77% and serum PSA levels by
about 42% and 68%, respectively. The activity of flavokawain B
against GM0308 tumors is especially noteworthy, since this tumor
was derived from a patient who was previously treated with ADT,
docetaxel plus carboplatin, and etoposide plus cisplatin. These
data suggest that flavokawain B may act through novel target
molecules to kill cancer cells of patients with advanced PCa
resistant to conventional therapy [27].
The mechanisms of kavalactones and flavokawain B mediated
AR down-regulation are different. Kavalactones act through a
mechanism of AR protein degradation, while flavokawain B
down-regulate Sp1 expression leading to a decrease of AR mRNA
levels. In addition, the kavalactone and flavokawain B combina-
tion results in an enhanced inhibitory effect on PCa cell growth
and AR expression. The transcriptional regulation of AR gene
remains largely unknown. Several groups reported that Sp1 is a
key regulator of AR gene transcription [13,14]. We demonstrated
that flavokawain B decreased Sp1 expression and its binding to the
AR promoter. However, it is still unclear why flavokawain B is
more potent to androgen-independent cell lines. A recent study
showed that purine-rich element binding protein (PUR) alpha
binds to a site near Sp1 in the AR promoter and suppress AR
expression, and that PUR alpha expression was associated AR
overexpression in androgen-independent cell lines [28]. Therefore,
the further investigation on the interaction between Sp1 and PUR
alpha under flavokawain B treatment may provide a novel
mechanism for flavokawain B induced AR down-regulation. In
addition, the mechanism of kavalactones induced AR protein
degradation would also deserve further investigation.
Figure 7. Kava root extract and FKB inhibit tumor growth,
reduce serum PSA levels and decrease AR expression in tumor
tissues in patient-derived PCa xenograft models. (A) and (B). The
mice bearing patient-derived PCa tumors were randomly divided into
treatment and control groups with similar pre-treatment serum PSA
levels in each group. Tumor volumes and serum PSA were recorded,
and presented as mean 6 SD. Wet weight of tumors is represented as
mean of tumors from individual mouse in each group. Bars, means 6
SD. The tumor volumes (repeated-measures analysis of variance
(ANOVA), p,0.01) and tumor weights (Student t test, P,0.01) of FKB
and the KRE treated mice were significantly lower than those of vehicle
control treated mice. (C). Immunohistology staining of AR expression in
tumor tissues. Control immunostaining was performed with IgG isotype
alone; Slides were counterstained with hematoxylin and photographed
using a light microscope. Original magnification: 6200. (D). AR positive
cells were counted in 12 fields in each group. The percentage of AR
positive cells was calculated and presented as mean 6 SD (the left two
panels). The mRNA levels of AR, PSA and TMPRSS2 in tumor tissues
treated with vehicle or FKB were analyzed by RT real-time PCR (the right
panel). Bars, means 6 SD. The percentages of AR positive cells are
significantly lower in the KRE and FKB treated groups than those in
vehicle control treated groups (Student t test, P,0.01). The mRNA levels
of AR, PSA and TMPRSS2 is lower in the KRE and FKB treated groups than
those in control groups (Student t test, P,0.01).
doi:10.1371/journal.pone.0031213.g007
Kava Root Extracts and Prostate Cancer
PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e31213In summary, the kava root extract and flavokawain B inhibited
tumor growth in clinically relevant xenograft models, decreased AR
expression in tumor tissues, and lowered serum PSA levels in tumor-
bearing mice. The down-regulation of AR expression by kavalac-
tones is associated with protein degradation. In contrast flavokawain
B decreases expression of both the full-length AR and AR splice
variants via inhibition of Sp1 mediated AR transcription. Flavoka-
wain B is more potent to castration-resistant PCa. Since traditional
kava preparation has been safely consumed for thousands of years, it
is unlikely that active components of kava extracts, including
kavalactones and flavokawains, are all toxic to human. Therefore,
the results obtained from this study clearly suggest a need for further
developing a safe and inexpensive kava product or its active
components for treatment and prevention of PCa and CRPC.
Figure 8. The effect of the kava root extract and FKB on mouse body and organ weight and food intake. (A). Body weights of vehicle,
the kava root extract, and FKB treated SCID mice were recorded weekly and presented as mean 6 SD. (B). Organ weights of vehicle, the kava root
extract, and FKB treated SCID mice at the end of the experiments were recoded and presented as mean 6 SD. (C). Food intakes of vehicle and the
kava root extract treated SCID mice were recorded weekly and presented as mean 6 SD.
doi:10.1371/journal.pone.0031213.g008
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